Plantar heel pain / plantar fasciopathy · Lab study · 2002
What did early studies of shockwave for heel pain report?
This early review gathered shockwave studies for long-lasting heel pain, mostly without comparison groups. Most reported that many people were satisfied with the result. The results were not combined.
- published studies
- 20
- people at least
- 1,601
- studies met its quality grades
- 8
Good to know: The only placebo-controlled trial was the authors’ own.
Ogden JA, Alvarez RG, Marlow M Foot & Ankle International, 2002 · Read the paper ↗
The treatment
- Devices and energy in included studies
- Electrohydraulic (OssaTron), electromagnetic (Siemens Sonocur, Dornier Compact S and Epos) and ballistic devices were combined. Table 2 labels each study high, low or ballistic energy; electrohydraulic studies mostly used one session and others three or more. Doses per study are not tabulated.
- Energy categories cited
- Citing Rompe, low energy was about 0.08 mJ/mm² at the treatment focus, medium up to 0.28 mJ/mm² and high above 0.6 mJ/mm². Anaesthesia was described as required for high-energy electrohydraulic treatment.
- Comparators
- Only one included trial was placebo-controlled. Several Rompe studies used "controls" receiving 10 to 100 shocks; most others had no control group.
Who took part
At least 1,601 people with heel pain for six months or more, in 20 mostly European studies from the 1990s.
Side effects
Some low-energy treatments were uncomfortable, and high-energy treatment needed numbing.
All the numbers and the full appraisal
What the full paper reports.
Published studies of extracorporeal shockwaves for chronic proximal plantar fasciitis (moderate to severe heel pain for at least six months at the fascia origin), mostly European series from the 1990s; at least 1,601 patients in 20 studies, 840 of them in the 8 studies rated A–C.
Studies by quality category1 reported outcome
Studies by quality category
Authors’ seven-level outcome-study classification (A–G, Table 1) Studies and patients
Of 20 published studies (at least 1,601 patients), 8 with 840 patients met categories A–C; only one, the authors’ own 322-patient OssaTron trial (Ogden 2001), was category A. The remaining Table 2 rows are category D (under one year of follow-up) or G, the two studies judged unacceptable.
Analysis details and source
Table 2 has 21 rows (one unnamed D row of 79 low-energy patients, apparently the low-energy arm of Jakobeit); counts of studies, patients and categories come from the text and table as printed.
Reported success rates1 reported outcome
Reported success rates
Study-defined "success" (complete or substantial relief or patient satisfaction) Percent of treated patients, as reported by each study
Table 2 lists success rates of 48% to 88% (88% in one category B study); the text gives a range of 34% to 88%. Success definitions differed between studies and usually meant satisfaction rather than complete relief. No rates were pooled and no treated-versus-control difference was calculated.
Analysis details and source
The 34% lower bound in the text does not appear in Table 2. Most rates are single-arm.
The one placebo-controlled trial1 reported outcome
The one placebo-controlled trial
Ogden 2001 multicentre electrohydraulic trial, as summarized here Narrative summary
The review states that, three months after one treatment, "56% more" treated than placebo patients met all success criteria, and that 94% of patients kept complete relief at one year. About 20% needed a second treatment. These figures are not reported with denominators here.
Analysis details and source
Summary by the trial’s own authors; the wording "56% more" is ambiguous (relative or absolute).
High versus low energy1 reported outcome
High versus low energy
Narrative comparison across studies Narrative summary
The authors conclude high-energy treatment works faster, with fewer sessions, in more patients. Support cited: Jakobeit (24.8% of 113 high-energy versus 11.4% of 79 low-energy patients pain-free after one treatment) and Buch’s low-energy series averaging four sessions. No randomized dose comparison was analysed.
Analysis details and source
Cross-study and nonrandomized comparisons cannot separate energy from device, protocol, population or outcome definition.
How treatment was delivered
Electrohydraulic (OssaTron), electromagnetic (Siemens Sonocur, Dornier Compact S and Epos) and ballistic devices were combined. Table 2 labels each study high, low or ballistic energy; electrohydraulic studies mostly used one session and others three or more. Doses per study are not tabulated.
Citing Rompe, low energy was about 0.08 mJ/mm² at the treatment focus, medium up to 0.28 mJ/mm² and high above 0.6 mJ/mm². Anaesthesia was described as required for high-energy electrohydraulic treatment.
Only one included trial was placebo-controlled. Several Rompe studies used "controls" receiving 10 to 100 shocks; most others had no control group.
Harms were not synthesized. The review calls the treatment safe, but reports no pooled adverse-event data; it notes that 20% of Russo’s low-energy patients asked for anaesthesia because of pain during treatment, that one study found low-energy treatment unpleasant for all patients, and that high-energy electrohydraulic treatment requires anaesthesia. Missing harm data are unknown, not zero. No funding or conflict-of-interest statement is printed.
Author-reported: one year of follow-up was set arbitrarily as the minimum; only one category A study existed; devices, energies, session numbers and success criteria differed, making studies hard to compare.
Extractor interpretation: despite the title, no statistical meta-analysis was done: no pooled estimate, no comparison with control groups, no heterogeneity or risk-of-bias assessment. Book chapters and meeting abstracts were included and grading was done by the authors without a described duplicate process.
Extractor interpretation: the only category A trial is the authors’ own OssaTron trial, and the conclusion ("safe and effective", preferable to cortisone injection and surgery) rests mainly on uncontrolled series and indirect comparisons. The paper prints no funding or conflict-of-interest statement.
Reporting: the text’s 34% lower success bound is absent from Table 2, whose lowest rate is 48%; Table 2 has 21 rows for 20 studies because one unnamed row appears to be the low-energy arm of Jakobeit. Search: MEDLINE 1990–2000 plus reference and book searches, no language restriction.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: one year of follow-up was set arbitrarily as the minimum; only one category A study existed; devices, energies, session numbers and success criteria differed, making studies hard to compare.
- Extractor interpretation: despite the title, no statistical meta-analysis was done: no pooled estimate, no comparison with control groups, no heterogeneity or risk-of-bias assessment. Book chapters and meeting abstracts were included and grading was done by the authors without a described duplicate process.
- Extractor interpretation: the only category A trial is the authors’ own OssaTron trial, and the conclusion ("safe and effective", preferable to cortisone injection and surgery) rests mainly on uncontrolled series and indirect comparisons. The paper prints no funding or conflict-of-interest statement.
- Reporting: the text’s 34% lower success bound is absent from Table 2, whose lowest rate is 48%; Table 2 has 21 rows for 20 studies because one unnamed row appears to be the low-energy arm of Jakobeit. Search: MEDLINE 1990–2000 plus reference and book searches, no language restriction.
Source-linked critical reading
Graded literature review titled meta-analysis, without statistical pooling
Technical source record
Full local scanned PDF read from page images: all 8 pages including Tables 1–2, Methods, Literature Search, Results, Discussion, affiliations and references. Underlying studies were not re-read.
This 2002 review gathered early shockwave studies for long-lasting heel pain, mostly uncontrolled, and found that most reported high satisfaction rates. It did not combine results statistically or compare treated people with untreated ones, and its single placebo-controlled trial was the authors’ own. It is useful history, not a measure of how much shockwaves help.
What do published studies of shockwave treatment for chronic proximal plantar fasciitis show, and how credible are they, when graded by study design and length of follow-up?
Literature review described as a meta-analysis: MEDLINE 1990–2000, reference lists and book searches without language limits; studies graded A–G by the authors’ criteria (Table 1). Success rates were tabulated, not statistically pooled, and no risk-of-bias tool was used.
Published studies of extracorporeal shockwaves for chronic proximal plantar fasciitis (moderate to severe heel pain for at least six months at the fascia origin), mostly European series from the 1990s; at least 1,601 patients in 20 studies, 840 of them in the 8 studies rated A–C.
Extracorporeal shockwaves to the plantar fascia origin from electrohydraulic, electromagnetic and ballistic devices, labelled high or low energy, given in one session (electrohydraulic) or usually three or more (other devices). No single protocol can be derived.
Only one included trial used placebo; some studies had low-dose "controls" of 10–100 shocks, and most had none. The review compares shockwave results narratively with published surgery, injection and conservative-care series.
Study-defined success, usually patient satisfaction or substantial relief, with categories A–C requiring at least one year of follow-up. No common outcome scale or time point was used.
Eight of 20 studies (840 patients) met categories A–C, and only the authors’ own 322-patient trial was randomized and placebo-controlled. Reported success ranged from 48% to 88% in Table 2 (34% to 88% in the text). The authors conclude shockwaves are safe and effective and that high energy works better, but these conclusions rest on uncontrolled and cross-study comparisons, without a pooled treatment effect.
Harms were not synthesized. The review calls the treatment safe, but reports no pooled adverse-event data; it notes that 20% of Russo’s low-energy patients asked for anaesthesia because of pain during treatment, that one study found low-energy treatment unpleasant for all patients, and that high-energy electrohydraulic treatment requires anaesthesia. Missing harm data are unknown, not zero. No funding or conflict-of-interest statement is printed.
No statistical pooling, control-group comparison, heterogeneity or risk-of-bias assessment despite the title; abstracts and book chapters included; success definitions varied; the only randomized trial is the authors’ own; the text’s 34% lower success bound differs from 48% in Table 2. No funding or conflict-of-interest statement is printed.
Shows how the early, mostly uncontrolled European literature looked by 2000. It cannot estimate how much shockwaves add beyond placebo or natural recovery and predates most randomized trials.
A prespecified systematic review of randomized sham-controlled trials with duplicate selection, risk-of-bias assessment, pooled effects on common pain and function scales, and harms data.
Read the original article.
Shockwave therapy for chronic proximal plantar fasciitis: a meta-analysis.
Ogden JA, Alvarez RG, Marlow M. · Foot & ankle international · 2002
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →